+4.6%
ADBE vs MRNA
+521.0%
-516.4%
-71.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.4% | +0.7% | -3.1% | -2.4% |
| 7D | -12.9% | -8.2% | -4.7% | -12.5% |
| 30D | -5.6% | +125.6% | -131.2% | -13.6% |
| 3M | +6.6% | +197.1% | -190.4% | -5.0% |
| 6M | -9.6% | +148.5% | -158.0% | -18.4% |
| YTD | -28.9% | +363.3% | -392.2% | -39.6% |
| 1Y | -28.9% | +462.0% | -490.9% | -41.0% |
| 3Y | -55.6% | +26.9% | -82.5% | -59.6% |
| 5Y | -62.2% | -69.6% | +7.4% | -63.8% |
| All | +4.6% | +521.0% | -516.4% | -10.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling